This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Warby Parker (WRBY), IDEAYA Biosciences (IDYA)

Tipranks - Tipranks - Sat Jun 13, 7:24AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Warby Parker (WRBY) and IDEAYA Biosciences (IDYA) with bullish sentiments.

Introducing TipRanks MCP for Agents

Warby Parker (WRBY)

According to TipRanks.com, Chen is a 4-star analyst with an average return of 3.3% and a 49.6% success rate. Chen covers the NA sector, focusing on stocks such as Brilliant Earth Group, Canada Goose Holdings, and Ermenegildo Zegna. ;'>

Warby Parker has an analyst consensus of Moderate Buy, with a price target consensus of $29.63.

See Insiders’ Hot Stocks on TipRanks >>

IDEAYA Biosciences (IDYA)

In a report released today, Robert Driscoll from Wedbush reiterated a Buy rating on IDEAYA Biosciences, with a price target of $58.00. The company’s shares closed last Thursday at $28.84.

According to TipRanks.com, Driscoll is a 4-star analyst with an average return of 6.0% and a 39.4% success rate. Driscoll covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Monte Rosa Therapeutics, and Arvinas Holding Company. ;'>

IDEAYA Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $54.00, which is a 94.3% upside from current levels. In a report issued on June 2, TipRanks – Google also upgraded the stock to Buy with a $32.00 price target.

Read More on WRBY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).